Non-invasive monitoring of cardiac function during haemodialysis

Impedance Cardiography Derived Cardiac Output in Hemodialysis Patients: A Study of Reproducibility and Comparison with Echocardiography

Background

Hemodialysis patients experience a variety of hemodynamic abnormalities that contribute to cardiovascular disease mortality which is the leading cause of death in these patients. Impedance cardiography has been utilized in order to monitor cardiac hemodynamics with lower cost and inconvenience, but it has not been appropriately validated in the hemodialysis population.

Aim

We repeatedly used impedance cardiography to assess short- (48 hours) and long-term (15 days) reproducibility of cardiac output measurements and we compared baseline impedance cardiography measurements with echocardiographic measurements.

Patients and Methods

We studied 109 stable hemodialysis patients, aged 59.70 ± 11.97 years being on hemodialysis for 67.59 ± 40.15 months, on a non-dialysis day. Cardiac output was obtained with the BioZ impedance cardiography system (Cardiodynamics, San Diego, Ca, USA). Baseline echocardiography was performed using a Hewlett-Packard Sonos 2500 (Andover, Mass., USA).

Results

The values of impedance cardiography derived cardiac output were 5.28 ± 0.79, 5.27 ± 0.75 and 5.25 ± 0.74 l/min at baseline (107 patients), 48 hours (107 patients) and 15 days (98 patients) respectively, showing high reproducibility. Bland and Altman analysis estimated that bias at 48 hours and at 15 days were: −0.013 (95% confidence intervals = −0.045 to 0.019) and 0.028, (95% confidence intervals = −0.044 to 0.101), respectively. In addition baseline impedance cardiography derived cardiac output was significantly correlated with the echocardiographic derived cardiac output (r = 0.9, p < 0.0001).

Conclusion

Impedance cardiography is a simple non invasive technique for cardiac output estimation in hemodialysis patients which has high reproducibility when performed under controlled conditions, and is closely correlated with echocardiographic measurements of cardiac output.

Noninvasive Measurement of Cardiac Output in Hemodialysis Patients by Task Force Monitor: A Comparison with the Transonic System

Cardiovascular disease is the leading cause of morbidity and mortality in maintenance hemodialysis (MHD) patients. The Transonic (TRS; Transonic Systems, Ithaca, NY) device is frequently used for determination of cardiac output (CO) by an indicator dilution technique. The Task Force Monitor (TFM; CN Systems, Graz, Austria) has gained attention as noninvasive tool for continuous beat-to-beat assessment of cardiovascular variables, including CO by impedance cardiography. Despite its use in cardiology and intensive care settings, the TFM has yet not been validated in dialysis patients. This study compares CO measurements in 12 MHD patients by TFM and TRS. Bland-Altman and regression analysis were used. CO was measured simultaneously by TRS and TFM. Average CO was 5.4 L/min by TRS and 5.0 L/min by TFM, respectively. Bland-Altman analysis revealed no significant systematic differences between the two methods (mean difference: 0.4 L/min; SD: 0.6; p > 0.05). Linear regression analysis showed significant correlation between both techniques (r = 0.802, p = 0.002). The SD of mean individual CO values was 1.1 L/min with TRS and 0.8 L/min with TFM, respectively.CO measured by TFM and TRS does not differ significantly, thus making the TFM an attractive noninvasive tool for the continuous beat-to-beat assessment of CO in MHD patients.

Impedance Cardiography: A Potential Monitor for Hemodialysis

BACKGROUND

Impedance cardiography (ICG) technology has improved dramatically, and at least one device now can give a measurement of fluid status by using thoracic fluid content (TFC), along with cardiac output (CO) and cardiac index (CI). With a built-in sphygmomanometer cuff, it can also provide blood pressure (BP) and systemic vascular resistance index (SVRI). A currently available small portable ICG that provides reliable measures of fluid status could be an ideal noninvasive monitor for hemodialysis (HD), with the potential of helping avoid significant hemodynamic instability during HD.

METHODS

A case series of patients with chronic renal failure was studied while undergoing HD using ICG (BioZ, CardioDynamics, Int. Corp., San Diego, CA). Parameters recorded at 15-min intervals included TFC, CI, BP (systolic, diastolic, and mean arterial), SVRI, and heart rate. Using the Pearson method, the percentage changes in each of the parameters during the HD session were correlated to the amount of fluid removed (FR), normalized to body weight.

RESULTS

Forty-one patients were enrolled, but six patients were excluded due to incomplete data; therefore, 35 patients (13 men and 22 women) formed the basis of the analysis. The age range was 28 to 87 (mean 55.1 +/- 16.1) years. The amount of FR was 2.88 +/- 1.13 L (37.3 +/- 14.6 ml/kg). TFC decreased in all patients during the HD session (average reduction 12.7 +/- 8 kohms(-1)); whereas all other hemodynamic parameters showed both increases and decreases. The correlation of change in TFC with FR was moderate (r = 0.579, P = 0.0003); other hemodynamic parameters showed a poor correlation with FR. Neither the standard hemodynamic parameters nor the ICG device's special parameters were able to identify the five patients in this series who experienced significant hemodynamic instability or intradialytic hypotension.

CONCLUSION

TFC, measured easily and noninvasively using ICG, correlates with the amount of fluid removed during HD. In comparison with the other hemodynamic parameters measured, TFC changed most consistently with fluid removal. Whether or not serial TFC measurements in a given patient at different HD sessions can guide the extent of FR will require additional study. This compact, easily operated, and nonobtrusive ICG device with the capability for continuously providing the standard hemodynamic parameters plus CO, TFC, and standard limb lead electrocardiography could replace current monitoring systems.

Cardiac performance and morphology in end-stage renal disease

Patients with end-stage renal disease (ESRD) experience a variety of hemodynamic and metabolic abnormalities that predispose to alterations in cardiac performance and morphology. High cardiac output related to renal anemia, hypertension, volume overload, and the arteriovenous fistula (in patients on hemodialysis) predispose to eccentric left ventricular (LV) hypertrophy. Hypertension, aortic stiffness, and aortic stenosis predispose to concentric LV hypertrophy. Most ESRD patients have a hybrid form of LV hypertrophy. LV hypertrophy is commonly accompanied by LV diastolic dysfunction. LV systolic dysfunction is less common. Newer dialytic techniques, excellent control of hypertension, and correction of renal anemia produce regression of LV hypertrophy. The effect of these interventions on LV systolic and diastolic function is less well established. Alterations in serum calcium, choice of dialysate base, hypoxia, and comorbid conditions may influence the effects of dialysis (particularly hemodialysis) on LV function. A variety of negative inotropic drugs may depress LV function in patients with ESRD.

Van Beaumont's formula is valid during haemodialysis. Spectrophotometric determination of body circulating haemoglobin

Van Beaumont's formula is a convenient method to calculate changes in plasma volume from changes in haematocrit. The calculation is based on the assumption of a constant body red-cell volume. In order to evaluate the validity of this assumption during isovolaemic haemodialysis, we measured body circulating haemoglobin, blood volume and plasma volume by carbon monoxide dilution. No change in body circulating haemoglobin or plasma volume occurred by either method. Therefore, we conclude that van Beaumont's formula is valid during isovolaemic haemodialysis.